Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation-Reference-Cited by-同舟云学术

Pirfenidone ameliorates pulmonary arterial pressure and neointimal remodeling in experimental pulmonary arterial hypertension by suppressing NLRP3 inflammasome activation

Published:2022-07 Issue:3 Volume:12 Page:
ISSN:2045-8940
Container-title:Pulmonary Circulation
language:en
Short-container-title:Pulm. circ.

Author:

Mavrogiannis Emmanouil¹²^ORCID,Hagdorn Quint A. J.¹,Bazioti Venetia²,Douwes Johannes M.¹,Van Der Feen Diederik E.¹,Oberdorf‐Maass Silke U.³,Westerterp Marit²,Berger Rolf M. F.¹

Affiliation:

1. Department of Pediatric Cardiology, Center For Congenital Heart Diseases, Beatrix Children's Hospital, University Medical Center Groningen University of Groningen Groningen The Netherlands

2. Department of Pediatrics, Beatrix Children's Hospital, University Medical Center Groningen University of Groningen Groningen The Netherlands

3. Department of Experimental Cardiology, University Medical Center Groningen University of Groningen Groningen The Netherlands

Funder

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pul2.12101

Reference34 articles.

1. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management